Membrane proteins: The key players of a cancer cell

Journal of Membrane Biology

Volumn 242, Issue 2, 2011, Pages 69-74

  Kampen, Kim R ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cancer therapy; Gene expression profiling; Membrane proteins; Nanocarriers; Receptor tyrosine kinases; Surgery

Indexed keywords

BCR ABL PROTEIN; CD59 ANTIGEN; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FOLATE RECEPTOR; GEFITINIB; MEMBRANE PROTEIN; MEMBRANE PROTEIN ZDHHC2; MITOGEN ACTIVATED PROTEIN KINASE; NANOCARRIER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAMUCIRUMAB; RITUXIMAB; SORAFENIB; SUNITINIB; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB;

ADVANCED CANCER; B CELL LYMPHOMA; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER SURGERY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE IMAGING; GENE EXPRESSION PROFILING; GLIOMA; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION PROFILING; HUMANS; MEMBRANE PROTEINS; NEOPLASMS;

EID: 79961170893     PISSN: 00222631     EISSN: 14321424     Source Type: Journal    
DOI: 10.1007/s00232-011-9381-7     Document Type: Review

References (44)

1. S Assouline JH Lipton 2011 Monitoring response and resistance to treatment in chronic myeloid leukemia Curr Oncol 18 e71 e83 21505592 10.3747/co.v18i2.391 1:STN:280:DC%2BC3MvkvFehsQ%3D%3D
2. JA Bonner PM Harari J Giralt RB Cohen CU Jones RK Sur D Raben J Baselga SA Spencer J Zhu H Youssoufian EK Rowinsky KK Ang 2010 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 21 28 19897418 10.1016/S1470-2045(09)70311-0 1:CAS:528:DC%2BC3cXjslKktA%3D%3D
3. H Chiun-Wei L Zibo C Hancheng S Tony SC Peter 2011 Novel alpha(2)beta(1) integrin-targeted peptide probes for prostate cancer imaging Mol Imaging 10 284 294
4. N Cook B Basu S Biswas P Kareclas C Mann C Palmer A Thomas S Nicholson B Morgan D Lomas B Sirohi AP Mander M Middleton PG Corrie 2010 A phase 2 study of vatalanib in metastatic melanoma patients Eur J Cancer 46 2671 2673 20800475 10.1016/j.ejca.2010.07.014 1:CAS:528:DC%2BC3cXht1WhtrvK
5. LM Crane M van Oosten RG Pleijhuis A Motekallemi SC Dowdy WA Cliby AG van der Zee GM van Dam 2011 Intraoperative imaging in ovarian cancer: fact or fiction? Mol Imaging 10 248 257 21521557
6. MS Czuczman SA Gregory 2010 The future of CD20 monoclonal antibody therapy in B-cell malignancies Leuk Lymphoma 51 983 994 20367564 10.3109/10428191003717746 1:CAS:528:DC%2BC3cXnt12lu7g%3D
7. PM Das AD Thor SM Edgerton SK Barry DF Chen FE Jones 2010 Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells Oncogene 29 5214 5219 20603612 10.1038/onc.2010.271 1:CAS:528: DC%2BC3cXotlWkurg%3D
8. R Fukuda B Kelly GL Semenza 2003 Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1 Cancer Res 63 2330 2334 12727858 1:CAS:528: DC%2BD3sXjtlGmtLc%3D (Pubitemid 36538645)
9. Y Gan C Shi L Inge M Hibner J Balducci Y Huang 2010 Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells Oncogene 29 4947 4958 20562913 10.1038/onc.2010.240 1:CAS:528:DC%2BC3cXns1Gjt7g%3D
10. AJ Gentles SK Plevritis R Majeti AA Alizadeh 2010 Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia JAMA 304 2706 2715 21177505 10.1001/jama.2010.1862 1:CAS:528:DC%2BC3cXhs1WhsrrF
11. SR Kantelhardt W Caarls AH de Vries GM Hagen TM Jovin W Schulz-Schaeffer V Rohde A Giese DJ Arndt-Jovin 2010 Specific visualization of glioma cells in living low-grade tumor tissue PLoS One 5 e11323 20614029 10.1371/journal.pone. 0011323
12. K Koretz S Bruderlein C Henne P Moller 1993 Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium Br J Cancer 68 926 931 7692919 10.1038/bjc.1993.456 1:CAS:528:DyaK2cXitFCjsrs%3D (Pubitemid 23315225)
13. MH Langenberg PO Witteveen NA Lankheet JM Roodhart H Rosing IJ van den Heuvel JH Beijnen EE Voest 2010 Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis Neoplasia 12 206 213 20126478 1:CAS:528:DC%2BC3cXhsFGrs7Y%3D
14. H Lee W Akers K Bhushan S Bloch G Sudlow R Tang S Achilefu 2011 Near-infrared pH-activatable fluorescent probes for imaging primary and metastatic breast tumors Bioconjug Chem 22 777 784 21388195 10.1021/bc100584d 1:CAS:528:DC%2BC3MXivFCns7s%3D
15. R Liu X Wang GY Chen P Dalerba A Gurney T Hoey G Sherlock J Lewicki K Shedden MF Clarke 2007 The prognostic role of a gene signature from tumorigenic breast-cancer cells N Engl J Med 356 217 226 17229949 10.1056/NEJMoa063994 1:CAS:528:DC%2BD2sXns12mug%3D%3D (Pubitemid 46143225)
16. J Mackey K Gelmon M Martin N McCarthy T Pinter M Rupin H Youssoufian 2009 TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer Clin Breast Cancer 9 258 261 19933083 10.3816/CBC.2009.n.044 1:CAS:528:DC%2BD1MXhsF2iu73E
17. Z Madjd SE Pinder C Paish IO Ellis J Carmichael LG Durrant 2003 Loss of CD59 expression in breast tumours correlates with poor survival J Pathol 200 633 639 12898600 10.1002/path.1357 1:CAS:528:DC%2BD3sXntl2nurc%3D (Pubitemid 36987313)
18. JH Maeng DH Lee KH Jung YH Bae IS Park S Jeong YS Jeon CK Shim W Kim J Kim J Lee YM Lee JH Kim WH Kim SS Hong 2010 Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer Biomaterials 31 4995 5006 20347138 10.1016/j.biomaterials.2010.02.068 1:CAS:528:DC%2BC3cXkvVejsrs%3D
19. KM McNeeley E Karathanasis AV Annapragada RV Bellamkonda 2009 Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors Biomaterials 30 3986 3995 19427688 10.1016/j. biomaterials.2009.04.012 1:CAS:528:DC%2BD1MXmvVykt74%3D
20. G Metro G Finocchiaro L Toschi S Bartolini E Magrini A Cancellieri R Trisolini L Castaldini G Tallini L Crino F Cappuzzo 2006 Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC) Rev Recent Clin Trials 1 1 13 18393776 10.2174/157488706775246157 1:CAS:528:DC%2BD28XitVGls78%3D
21. L Milane Z Duan M Amiji 2011 Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells Mol Pharm 8 185 203 20942457 10.1021/mp1002653 1:CAS:528:DC%2BC3cXhsVOksbbI
22. M Noguchi Y Mizukami K Kinoshita M Earashi M Thomas I Miyazaki 1994 The prognostic significance of epidermal growth factor receptor expression in breast cancer Surg Today 24 889 894 7894186 10.1007/BF01651004 1:STN:280: DyaK2M3gtFClsA%3D%3D (Pubitemid 24358757)
23. AF Okines A Dewdney I Chau S Rao D Cunningham 2010 Trastuzumab for gastric cancer treatment Lancet 376 1736 1737 21093643 10.1016/S0140-6736(10) 62127-7
24. T Oyama Y Miyoshi K Koyama H Nakagawa T Yamori T Ito H Matsuda H Arakawa Y Nakamura 2000 Isolation of a novel gene on 8p21.3-22 whose expression is reduced significantly in human colorectal cancers with liver metastasis Genes Chromosomes Cancer 29 9 15 10918388 10.1002/1098-2264(2000)9999:9999<::AID- GCC1001>3.0.CO;2-# 1:CAS:528:DC%2BD3cXmtVCis74%3D (Pubitemid 30620493)
25. D Peer JM Karp S Hong OC Farokhzad R Margalit R Langer 2007 Nanocarriers as an emerging platform for cancer therapy Nat Nanotechnol 2 751 760 18654426 10.1038/nnano.2007.387 1:CAS:528:DC%2BD2sXhtlyktL%2FI (Pubitemid 350223348)
26. H Poptani 2010 EGFR targeted fluorescence imaging in gliomas Acad Radiol 17 1 2 19969252 10.1016/j.acra.2009.10.025
27. GJ Roboz FJ Giles AF List JE Cortes R Carlin M Kowalski S Bilic E Masson M Rosamilia MW Schuster D Laurent EJ Feldman 2006 Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome Leukemia 20 952 957 16617323 10.1038/sj.leu.2404213 1:CAS:528:DC%2BD28XkvVymurg%3D (Pubitemid 43797284)
28. JF Sah S Balasubramanian RL Eckert EA Rorke 2004 Epigallocatechin-3- gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases J Biol Chem 279 12755 12762 14701854 10.1074/jbc.M312333200 1:CAS:528:DC%2BD2cXitl2gt7Y%3D (Pubitemid 38445847)
29. L Sampath S Kwon S Ke W Wang R Schiff ME Mawad EM Sevick-Muraca 2007 Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer J Nucl Med 48 1501 1510 17785729 10.2967/jnumed.107.042234 1:CAS:528:DC%2BD2sXhtFGgsLjE (Pubitemid 47397400)
30. T Schlomm P Kirstein L Iwers B Daniel T Steuber J Walz FH Chun A Haese J Kollermann M Graefen H Huland G Sauter R Simon A Erbersdobler 2007 Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer Clin Cancer Res 13 6579 6584 18006757 10.1158/1078-0432.CCR-07-1257 1:CAS:528:DC%2BD2sXhtlSmu7jE (Pubitemid 350206791)
31. V Serra M Scaltriti L Prudkin PJ Eichhorn YH Ibrahim S Chandarlapaty B Markman O Rodriguez M Guzman S Rodriguez M Gili M Russillo JL Parra S Singh J Arribas N Rosen J Baselga 2011 PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer Oncogene 30 2547 2557 21278786 10.1038/onc.2010.626 1:CAS:528:DC%2BC3MXht12msLs%3D
32. M Shimizu Y Shirakami H Sakai Y Yasuda M Kubota S Adachi H Tsurumi Y Hara H Moriwaki 2010 (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells Chem Biol Interact 185 247 252 20346928 10.1016/j.cbi.2010.03.036 1:CAS:528:DC%2BC3cXltF2hsbo%3D
33. PM Smith-Jones N Pandit-Taskar W Cao J O'Donoghue MD Philips J Carrasquillo JA Konner LJ Old SM Larson 2008 Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003 Nucl Med Biol 35 343 351 18355690 10.1016/j.nucmedbio.2007.12.008 1:CAS:528:DC%2BD1cXjs1KitLo%3D (Pubitemid 351381971)
34. JA Sosman I Puzanov MB Atkins 2007 Opportunities and obstacles to combination targeted therapy in renal cell cancer Clin Cancer Res 13 764s 769s 17255307 10.1158/1078-0432.CCR-06-1975 1:CAS:528:DC%2BD2sXoslWjsg%3D%3D
35. JL Spratlin RB Cohen M Eadens L Gore DR Camidge S Diab S Leong C O'Bryant LQ Chow NJ Serkova NJ Meropol NL Lewis EG Chiorean F Fox H Youssoufian EK Rowinsky SG Eckhardt 2010 Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 780 787 20048182 10.1200/JCO.2009.23.7537 1:CAS:528:DC%2BC3cXksVyrtr0%3D
36. LS Steelman WH Chappell SL Abrams RC Kempf J Long P Laidler S Mijatovic D Maksimovic-Ivanic F Stivala MC Mazzarino M Donia P Fagone G Malaponte F Nicoletti M Libra M Milella A Tafuri A Bonati J Bäsecke L Cocco C Evangelisti AM Martelli G Montalto M Cervello JA McCubrey 2011 Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging Aging (Albany NY) 3 192 222 1:CAS:528:DC%2BC3MXkvFKjt70%3D
37. Themelis G, Harlaar NJ, Kelder W et al (2011) Enhancing surgical vision by using real-time imaging of alpha(v)beta (3)-integrin targeted near-infrared fluorescent agent. Ann Surg Oncol. doi: 10.1245/s10434-011-1664-9
38. S Toikkanen H Helin J Isola H Joensuu 1992 Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up J Clin Oncol 10 1044 1048 1351537 1:STN:280:DyaK38zgtVCjtw%3D%3D
39. GA Viani SL Afonso EJ Stefano LI De Fendi FV Soares 2007 Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 153 17686164 10.1186/1471-2407-7-153 (Pubitemid 47354734)
40. JA Woyach AS Ruppert NA Heerema BL Peterson JG Gribben VA Morrison KR Rai RA Larson JC Byrd 2011 Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 J Clin Oncol 29 1349 1355 21321292 10.1200/JCO.2010.31.1811 1:CAS:528:DC%2BC3MXntlKlsbo%3D
41. C Xu M Jung M Burkhardt C Stephan D Schnorr S Loening K Jung M Dietel G Kristiansen 2005 Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy Prostate 62 224 232 15389793 10.1002/pros.20134 1:CAS:528:DC%2BD2MXhsVKltb8%3D (Pubitemid 40129060)
42. T Yau P Chan R Pang K Ng ST Fan RT Poon 2010 Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma Cancer 116 5022 5029 20629034 10.1002/cncr.25372 1:CAS:528:DC%2BC3cXhsVymtL%2FO
43. You B, Chen EX (2011) Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. J Clin Pharmacol. doi: 10.1177/0091270010395940
44. Zhang Y, Wang L, Zhang M, Jin M, Wang X (2011) Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Atk-Erk pathway. J Cell Physiol. doi: 10.1002/jcp.22722